Sonoma Pharmaceuticals reported record quarterly revenue of $5.6 million for the three months ended September 30, 2025, up 57% from $3.58 million in the same period a year earlier. Six‑month revenue rose 38% to $10.8 million from $7.8 million.
U.S. revenue increased 115% to $3.2 million from $1.4 million, largely driven by the launch of its HOCl‑based diaper rash product in Walmart and expanded distribution of its wound cleanser through Medline. International revenue grew 12% to $2.4 million.
Net loss per share fell 46% to $0.85 from $1.78, and the company reported a net loss of $1.2 million for the quarter, down from $2.6 million a year earlier. Cost‑control initiatives focused on manufacturing efficiencies and reduced marketing spend on legacy products.
Management reiterated its guidance for the full fiscal year, projecting revenue of $22–24 million and a net loss per share of $1.5–$1.7. The company also highlighted ongoing regulatory approvals, including FDA 510(k) clearance for its eye care line and MoCRA registration for its facial spray.
CEO Amy Trombly emphasized that the company’s stabilized HOCl technology continues to drive demand across wound care, eye, oral, dermatology, and animal health markets, and that the company remains focused on scaling its OTC presence while working toward profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.